To date, studies on the application of mesodermally derived mesenchymal-, hematopoietic-and vascular-lineage cells for cell therapy have provided either poor or insufficient data. The results are equivocal with regard to therapeutic efficiency and yield. Since the establishment of human embryonic stem cells (hESCs) in 1998, the capacity of hESCs to differentiate into various mesodermal lineages has sparked considerable interest in the regenerative medicine community, a group interested in generating specialized cells to treat patients suffering from degenerative diseases. Even though hESCs are sensitive, effective methods for guiding the differentiation of hESCs into specific mesodermal cell types are still being developed. In addition, to understand the functional properties of hESC derivatives, numerous animal model studies have been performed by many research groups over the last decade. In this review, we describe and summarize the protocols currently used for differentiation of hESCs into multiple mesodermal lineages and their therapeutic efficiency in different animal models. Furthermore, we discuss the technical hurdles associated with each protocol and the safety of hESC derivatives for therapeutic applications. Technical improvement of the methods used to produce hESC derivatives for therapeutic use in patients with degenerative diseases should remain an objective of future studies, as should the development of effective and stable induction systems.
Introduction
Mesenchymal stem cells (MSCs), endothelial progenitor cells (EPCs) and hematopoietic stem cells (HSCs) derived from adult tissues have been regarded as promising candidate sources for cell therapy applications. Numerous studies have assessed how this therapy could be used to treat ischemic damage and leukemia or promote bone regeneration. In spite of the therapeutic potential of these adult cells, it can be difficult to obtain a sufficient number of cells for treatment of patients with severe diseases. Human embryonic stem cells (hESCs), which are immortal and pluripotent, have been recognized by the field of regenerative medicine as an alternative source for cell therapy that would avoid the limitations of adult-derived cells (1) . To date, several groups have developed hESC differentiation systems to induce the development of specific cell types. Embryoid body (EB) formation (2) , specific growth factor treatment (3), and co-culture with supporting cells encompass the representative induction systems required to simulate the environment experienced during embryonic development (4) . A virus-based genetic modification system was recently developed to enrich the differentiation efficiency of hESCs (5) . Effective differentiation of mesodermal lineage cells from hESCs has been achieved using these systems. The differentiated cells exhibited appropriate functional properties in animal model studies as well as in in vitro studies. Although development of effective techniques for differentiating hESCs into specific cell types is crucial for obtaining sufficient cell numbers, the safe use of hESC derivatives for cell therapy is recognized as a more important clinical parameter. Therefore, recent work in this field has focused on evaluating the safety of differentiated cells as well as developing effective and stable hESC differentiation techniques.
Representative protocols for mesodermal induction using hESCs
Generation of defined mesodermal subtypes from hESCs requires appropriate control of mesodermal induction. At least four main strategies have been used for induction of hESCs into mesodermal subtype cells in vitro: EB formation in suspension culture, co-culture with supporting cells, growth factor treatment and genetic modification ( Fig. 1) .
EBs are formed in suspension culture through aggregation of hESCs. The interactions of cells within the EB are known to mimic the normal course of embryogenesis (2) . Because the EBs contain all three germ layers, EB culture is utilized as a general induction tool for the differentiation of hESCs. Within the mesodermal subtype, contracting cardiomyocytes spontaneously differentiated from EBs when the hESC media lacked bFGF (6) . With respect to the localization of cell populations in differentiating EBs, Cho et al. first identified the specific location of endothelial cells, and Kim et al. effectively isolated an endothelial cell population within the EB using a two-step enzyme treatment method (7, 8) . Likewise, Lee et al. reported that the cells in the outer region of the EB are characteristically MSCs (9) (Fig. 1A ). Co-culture based strategies for differentiation of mesodermal subtypes have been reported for hematopoietic, osteogenic and cardiomyocyte lineages. For example, bone marrow-derived stromal cell lines, e.g., OP9, MS5 and S17, were used for hematopoietic lineage induction (10) (11) (12) (13) (14) .
Similarly, bone tissue-derived primary cells induced the direct differentiation of osteogenic cells from hESCs (15) . Lastly, a visceral endoderm-like cell line, END2, supported the enrichment of cardiomyocytes from hESCs (4) (Fig. 1B) .
In past years, various growth factors were required for effective differentiation of hESCs. Exposure of hESCs to eight typical growth factors can induce the differentiation of specific lineages (2) . It is well known that BMP signaling plays a major role in mesodermal development (16) . Laflamme et al. induced cardiomyocyte differentiation of hESCs using BMP4 and activin treatment (17) . As an alternative growth factor-based strategy, Kaufman et al. generated hematopoietic lineage cells using a combination of growth factors that included SCF, GM-CSF, IL-3, IL-6, G-CSF and EPO (14) (Fig. 1C) .
Recently, genetic modification techniques have been employed to directly induce hESC differentiation and permit effective isolation of specific cell types. In the case of direct differentiation, Kim et al. successfully generated osteogenic cells from hESCs with high yield by inducing the expression of an osteogenic-specific gene, cbfa-1, using a lentiviral vector system (5). For purification of cardiomyocytes, Huber et al. produced differentiated hESCs by EB formation expressing GFP under the control of the cardiomyocyte-specific MLC2v promoter via transduction with a recombinant lentiviral vector system (18) . Furthermore, James et al. used an endothelial cell specific VEcadherin promoter driving GFP to define vasculogenic developmental pathways and enrich endothelial cell differentiation (19) (Fig. 1D) .
Differentiation of endothelial and vascular progenitor cells
Neovascularization refers to the formation of new blood vessels, either from the preexisting vascular network (angiogenesis) or through a de novo process involving circulating endothelial progenitor cells (EPCs) (vasculogenesis) (20) . Over the past decade, EPCs have attracted increasing attention, and many researchers have reported the identification and isolation of EPCs participating in vasculogenesis. In 1997, Asahara and colleagues reported that EPCs were present in the peripheral blood and of human bone marrow (BM) origin (21) . Later studies indicated that human cord blood is a rich source of EPCs (22) . The role of EPCs in the endogenous maintenance and repair of damaged endothelium is now being intensively investigated, as is their therapeutic potential for vascular regenerative medicine (23, 24) . In particular, cell therapies using EPCs have proven beneficial in patients with coronary artery disease (23) . Despite their obvious angiogenic potential for clinical treatment of ischemic diseases, the mechanisms by which EPCs enhance endothelial repair and neovascularization remain controversial. In addition, isolating EPCs in sufficient numbers requires a large amount of blood or BM (25) . This can cause complications in patients with severe cardiovascular disease, particularly myocardial infarction. Because of the limited supply and increasing demand for EPCs for clinical applications, the development of methods to expand EPC populations has become a priority.
On the other hand, hESCs have an extensive self-renewal ability and unlimited proliferation potential as well as functional multilineage differentiation capacity; hence, they are ideal resources for regenerative medicine, which requires a large number of transplant cells (1, 26) . Therefore, hESC-derived endothelial cells (hESC-ECs) could feasibly represent a novel cell source for the treatment of ischemic cardiovascular diseases. However, a major challenge of hESC-based therapy is the generation of sufficient numbers of differentiated endothelial cells. The efficiency of endothelial differentiation using the EB system is typically low, ranging from 1% to 3% (26, 27) . Moreover, it is difficult to obtain single cells from EBs by enzyme digestion as cell viability is reduced during this harsh digestion step. Several investigators have introduced effective approaches to increase endothelial differentiation efficiency (Table 1) . hESC-ECs can be generated by two main approaches, either spontaneous differentiation of embryoid bodies (EBs) (8, (26) (27) (28) , also called three-dimensional differentiation (3D), or two-dimensional differentiation (2D) (14, (29) (30) (31) . For 3D differentiation, hESCs need to be cultured in low-attachment dishes for 9∼13 days (8, (26) (27) (28) . Different media have been used in this system, in the presence or absence of growth factors. hESCs cultivated as EBs spontaneously differentiate into endothelial cells and form blood vessel-like structures. In addition, using whole-mount immunostaining for PECAM1 (CD31), Kim et al. reported that the most potent endothelial marker expression was observed in the central region of the EB (7). To isolate the latent endothelial population, different microenvironmental conditions have been used, with or without extracellular matrix (8, 32) , prior to digesting the EBs into single cells. Differentiated endothelial cells, or hemangioblasts, were then sorted by fluorescence-activated cell sorting (FACS) or magnetic-activated cell separation (MACS). In some cases, specific culture systems allowed the endothelial population to be naturally selected without the use of a cell-sorting technique. 
(VEGF) or platelet-derived growth factor-BB (PDGF-BB), respectively (30, 34) . Combined transplantation of hESC-ECs and hESC-derived smooth muscle cells (hESC-SMCs) can augment reparative neovascularization and contribute to newly formed vessels in ischemia models far more effectively than endothelial cell transplantation alone (30) . This may represent a major novel strategy for vascular regenerative medicine.
Both in vitro assays and in vivo transplantation have been used to characterize hESC-ECs. After subculturing, these cells express CD31, CD34, Flk-1, VE-cadherin, and vWF which are capable of DiI-ac-LDL uptake in vitro, and hESC-ECs can form tube-like structures within Matrigel plugs in vivo (29) . Therapeutic angiogenesis/vasculogenesis is a promising option for treating peripheral artery disease, ischemic heart disease, and cerebral ischemia. Clinical trials have confirmed that autologous cell therapies using bone marrow-derived or circulating blood-derived progenitor cells are safe and provide therapeutic effects (35) . However, low numbers and impaired function of patient-derived progenitor cells may limit the efficiency of autologous stem cell therapy (36) . Animal experiments have also demonstrated promising effects of hESC-EC transplantation ( Table 2 ). For example, hESC-ECs grown with a mouse mesenchymal precursor cell line (10T1/2) in a fibronectin-collagen gel could form cord-like networks upon transplantation into the cranial windows of SCID mice (29) . Following intravenous injection of tetramethylrhodamine-labeled dextran to enhance the contrast of perfused vessels, blood flow was observed in these engineered vessels, suggesting successful integration into the recipient's vascular network. In mouse models of hindlimb ischemia, hESC-ECs transplanted alone or in combination with smooth muscle cells (SMCs) derived from hESC (hESC-SMCs) could improve blood perfusion and limb salvage by facilitating postnatal neovascularization (8, 30, 34) . Recently, transplantation of hESC-ECs and mural cells was shown to improve therapeutic vascular regeneration and reduce the infarct area after stroke (37) .
Differentiation of hemangioblast and hematopoietic lineage cells
Hematopoietic stem cells (HSCs) are multipotent cells that can be isolated from the bone marrow (BM), peripheral blood (PB), or umbilical cord blood (CB). These cells develop into many different mature blood cell lineages, including myeloid (monocytes, macrophages, neutrophils, basophils, eosinophils, erythrocytes, megakaryocytes/platelets and dendritic cells) and lymphoid lineages (T-cells, B-cells and NK-cells) (38) . Despite the proven quality of adult body-origin HSC transplants, challenges remain for feasible HSC-based treatment; there is always a shortage of HLA-matched donors, and in vitro expansion of HSCs for transplantation is technically difficult (39) . To avoid the aforementioned problems related to the use of adult cells as a source of HSCs, many researchers have tried to derive HSCs from hESCs. Because hESCs can continuously proliferate in vitro, they are a potential source of HSCs that could yield an unlimited supply of cells for clinical therapies without relying on matched donors. hESC-derived HSCs demonstrate self-renewal, multipotency and regenerative capacity, depending on the culture conditions used to differentiate the hESCs (40) . Hence, hESCs represent a possible alternative source of mature blood cells (10) . Because hESC-derived RBCs and platelets lack nuclei, they are expected to bypass immune rejection responses in the host. Methods for direct differentiation of hESCs to hematopoietic lineage cells have been optimized by several research groups using both co-culture with stromal cells, which simulate the hematopoietic environment (14, 41) , and EB-mediated differentiation in conjunction with cytokine treatment to enhance hematopoietic development (42, 43) . Other research groups have induced hESCs to form hemangioblasts instead of directly differentiating into HSCs. Hemangioblasts are common mesodermal precursor cells for the hematopoietic and vascular lineages that reside in the developing yolk sac, which gives rise to both blood cells and blood vessels (28, 44 (32) . Studies indicate that the initial clinical use of hESC-derived hemangioblasts/HSCs hematopoietic stem cells will probably involve transfusion treatments to support erythrocyte and megakaryocyte/platelet development. Lu et al. generated mature, enucleated RBCs from hESCs by both EB formation and co-culturing with stromal cells using a serum-free system (10). Lapillonne et al. produced RBCs from hiPSCs using EB formation and cytokine treatment (11) . Recently, Takayama et al. produced functional platelets capable of thrombus formation in vivo from hiPSCderived hematopoietic cells using a stromal cell co-culture system (12) . In addition, Lu et al. reported that platelets efficiently generated from hESC-derived hemangioblasts in a serum-free system are functional in vitro and in mice (13) . The various differentiation procedures introduced above have been adopted for many productive studies on HSCs and hemangioblasts, especially on their functionality in vitro (Table 1) . However, no rigorous, functional, in vivo studies of HSCs have been reported to date; only conformation that hESC-derived hemangioblasts can form platelets in mice (Table 2) . Therefore, future studies will need to show that hESC-derived HCs (RBCs and platelets) are safe and functional in animals.
Differentiation of mesenchymal stem cells
Mesenchyme is defined as mesodermal tissue corresponding to the middle layer formed upon epithelial-tomesenchymal transitions (EMT) during embryonic development (45) . Since MSCs were first derived from bone marrow in the adult human body (46), MSCs with similar characteristics have been collected from various other tissues, including peripheral blood and adipose tissue (47, 48) . Recently, MSCs have also been derived from fetal sources, such as cord blood and amnion (49, 50) . In general, MSCs are characterized by the combinatorial expression patterns of various surface markers, including CD105, CD73, CD166, HLA Class I, CD44, CD 146 and CD90, which are positively expressed. Conversely, CD45, CD34, CD14, CD31, CD19 and HLA-DR (51, 52) are not expressed by MSCs. Although MSCs do not have defined unique characteristics, unlike more common specific cell types, because of their high proliferation and multipotent differentiation capacity, MSCs are now being used in many areas as a cell source for regenerative therapy (47, 49, 50) . However, adult MSCs display irregular proliferation patterns when sub-cultured for long periods, thus requiring repeated preparations from adults, making research on the topic more difficult (53) . Therefore, to bypass the limitations of working with MSCs, hESCs can be used instead; in fact, several research groups have reported the generation of MSCs from hESCs (Table 1) developed an hESC monolayer differentiation culture system that does not rely on feeder cells or sorting to produce mesenchymal progenitor cells. These hESCs appeared to undergo EMT events prior to the generation of mesenchymal progenitor cells. Such cells were highly proliferative and demonstrated the capacity differentiate into osteogenic and chondrogenic cell types, but not adipocytes (57) . To that end, most of the previous studies on hESC-derived MSCs were limited to in vitro differentiation. The potential use of hESCs to replace functional losses of particular tissues without any detrimental in vivo side effects may depend on efficient differentiation protocols for deriving tissue-specific progenitor cells. To conquer these challenges, new methods of obtaining MSCs by naturally inducing differentiation without xenogenic feeders or sorting processes are being developed and reported (9, 58) . Hwang et al. described an efficient method for inducing hESC differentiation into MSCs that have multilineage differentiation potential and are capable of differentiating into adipose, cartilage, and osteogenic cell types in vitro. Furthermore, normal cartilaginous structure was achieved in athymic rat osteochondral lesions after treatment with chondrogenically committed hESC-derived MSCs (58) ( Table 2 ). Lee et al. derived MSCs from three different hESC lines (SNUhES3, CHA3-hESC, and H9) via EB formation and subsequent culture with sequential media changes, thereby avoiding the use of inductive xenogenic feeders or mechanical selection procedures. These cells differentiated into multiple lineages, including osteocytes, chondrocytes, adipocytes, and myocytes in vitro. Moreover, the group demonstrated that transplantation of hESC-derived MSCs into the cryo-injured myocardium of C57BL/6J mice resulted in smaller infarct size in injured areas and improved cardiac function as measured by echocardiography (9) ( Table 2 ).
Obstacles to hESC research
Although hESCs have been widely recognized as a new cell source for regenerative therapy (1), the major hurdle delaying the utilization of hESCs in currently untreatable human diseases is the requirement to demonstrate the safety of hESC derivatives.
Most hESC lines were generated in the presence of animal serum and animal-derived feeder cells. Such hESC lines that were exposed to animal components should not be used for human therapeutic applications due to the risk of graft rejection and pathogenic transmission of diseases from animal sources. Several different types of human feeders, including human adult skin fibroblasts, foreskin fibroblasts, and placental fibroblasts, have been tested with hESC cultures and reportedly support prolonged growth of undifferentiated hESCs (59, 60) . More recently, a completely defined, animal-free medium, TeSR1, which does not contain bovine serum albumin (BSA), has been introduced (61) . In addition, researchers have demonstrated that a poly-D-lysine coating can efficiently support cell attachment and growth of hESC lines on culture plates (62) . Considering that poly-D-lysine is a widely used synthetic polypeptide that is pathogen-free, inexpensive, and easy to handle compared to Matrigel, this new method may provide easy access to the animal-free environments critical for hESC-mediated cell therapeutic strategies.
Another major risk involving the use of hESCs is the possibility of cell misbehavior following transplantation. This potentially serious complication can occur if any transplanted undifferentiated hESCs form teratomas (27) . Careful and precise protocols for collecting only differentiated cells are necessary to circumvent this hazard.
Lastly, during prolonged maintenance of undifferentiated hESCs in vitro, chromosomal instability can give rise to numerous changes in ploidy, especially in chromo-somes 12 and 17 (63) . Chromosomal instability seriously affects cell function and is well known to be a hallmark of many tumors (64, 65) . In addition, the generation of chromosomal instability by the presence of extra centrosomes can give rise to multiple aneuploid daughter cells with proliferative advantages, chemoresistance or metastatic potential (66, 67) . Their potential for tumor progression is a significant challenge facing the safe therapeutic application of hESCs. Recently, Moon et al. demonstrated aberrant cell division in karyotypically abnormal hESCs during in vitro culture. These authors subsequently showed a post-transplant tumor-like tissue growth arising from the hESC transplant derivatives (68) . These results emphasize that sustaining normal human chromosome number during in vitro culture and differentiation is indispensable for safe transplantation of hESC derivatives for therapeutic use.
Conclusions and future directions
Because hESC derivatives are quite similar to their adult counterparts, hESCs, which are pluripotent and immortal, can provide an alternative source of differentiated cells while bypassing the limitations associated with adult cells. The development of effective differentiation techniques holds great promise for several clinical areas, including treatment of incurable diseases. Over the last decade, significant improvements have been made in methods for inducing hESCs to differentiate into mesodermal lineage cells, including MSCs, HCs, HSCs, hemangioblasts, EPCs and VPCs. The most successful techniques rely on exposure to various mesoderm-associated factors, replicating in vivo events of mesoderm development or allowing for systematic induction with supporting cells (Fig. 1 and Table 1 ). Furthermore, functional properties of hESC derivatives have been studied using animal disease models (Table 2) , and some US groups have recently received FDA approval to initiate clinical experiments using hESC derivatives for cell therapy. These recent developments are encouraging to hESC research groups worldwide. Nevertheless, the clinical safety of undifferentiated or differentiated hESCs remains a challenge for therapeutic applications. First, to overcome current limitations regarding the safety of undifferentiated hESCs, researchers have tried to generate complete xeno-free hESC lines and culture systems that exclude animal serum and animal feeder conditions. Next, to reduce the risk of tumorigenicity of hESC derivatives, researchers have developed ways to screen hESC derivatives for contamination from undifferentiated hESCs and have optimized chromosomally stable induction systems in vitro. In this review, we provide an outline of in vitro hESC-derived mesodermal lineage differentiation techniques, describe their functional properties in vivo and discuss the current limitations of hESC derivatives. Finally, we present data concerning the safety of various differentiation systems as well as methods to improve efficacy for the clinical application of hESCs in the field of regenerative medicine.
